ID   UKF-NB-3
AC   CVCL_9904
SY   UKF-NB3
DR   IARC_TP53; 26506
DR   Wikidata; Q54990311
RX   CelloPub=CLPUB00123;
RX   PubMed=8949988;
RX   PubMed=9201287;
RX   PubMed=16142320;
RX   PubMed=16151587;
RX   PubMed=17505515;
RX   PubMed=19147553;
RX   PubMed=22170099;
RX   PubMed=22476102;
RX   PubMed=24466371;
RX   PubMed=25749379;
RX   PubMed=27517323;
RX   PubMed=27735941;
RX   PubMed=31581737;
CC   Doubling time: 22 +- 1.9 hours (PubMed=16142320).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): PubMed=31581737
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 13
ST   D18S51: 16,18
ST   D19S433: 14
ST   D21S11: 29,33.2
ST   D2S1338: 16,21
ST   D3S1358: 15,18
ST   D5S818: 11
ST   D7S820: 10,11
ST   D8S1179: 9,10
ST   FGA: 19,25
ST   Penta D: 8,15
ST   Penta E: 12
ST   TH01: 9,9.3
ST   TPOX: 8
ST   vWA: 15,18
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 14
//
RX   CelloPub=CLPUB00123;
RA   Cinatl J., Gussetis E.S., Cinatl J. Jr., Ebener U., Mainke M.,
RA   Schwabe D., Doerr H.-W., Kornhuber B., Gerein V.;
RT   "Differentiation arrest in neuroblastoma cell culture.";
RL   J. Cancer Res. Clin. Oncol. 116 Suppl. 1:9-9(1990).
//
RX   PubMed=8949988; DOI=10.1097/00001813-199609000-00008;
RA   Cinatl J. Jr., Cinatl J., Scholz M., Hernaiz Driever P., Henrich D.,
RA   Kabickova H., Vogel J.-U., Doerr H.-W., Kornhuber B.;
RT   "Antitumor activity of sodium valproate in cultures of human
RT   neuroblastoma cells.";
RL   Anticancer Drugs 7:766-773(1996).
//
RX   PubMed=9201287;
RA   Cinatl J. Jr., Hernaiz Driever P., Cinatl J., Ruckert D.G.,
RA   Gumbel H.O., Rabenau H.F., Kornhuber B., Doerr H.-W.;
RT   "Increased efficacy of aphidicolin killing of human neuroblastoma
RT   cells in vitro by encapsulation in liposomes.";
RL   Neoplasma 44:91-95(1997).
//
RX   PubMed=16142320; DOI=10.3892/ijo.27.4.1029;
RA   Kotchetkov R., Hernaiz Driever P., Cinatl J., Michaelis M.,
RA   Karaskova J., Blaheta R.A., Squire J.A., von Deimling A., Moog J.,
RA   Cinatl J. Jr.;
RT   "Increased malignant behavior in neuroblastoma cells with acquired
RT   multi-drug resistance does not depend on P-gp expression.";
RL   Int. J. Oncol. 27:1029-1037(2005).
//
RX   PubMed=16151587;
RA   Bedrnicek J., Vicha A., Jarosova M., Holzerova M., Cinatl J. Jr.,
RA   Michaelis M., Cinatl J., Eckschlager T.;
RT   "Characterization of drug-resistant neuroblastoma cell lines by
RT   comparative genomic hybridization.";
RL   Neoplasma 52:415-419(2005).
//
RX   PubMed=17505515; DOI=10.1038/sj.bjc.6603777;
RA   Blaheta R.A., Michaelis M., Natsheh I., Hasenberg C., Weich E.,
RA   Relja B., Jonas D., Doerr H.-W., Cinatl J. Jr.;
RT   "Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant
RT   neuroblastoma tumour cells to endothelium.";
RL   Br. J. Cancer 96:1699-1706(2007).
//
RX   PubMed=19147553; DOI=10.1158/0008-5472.CAN-08-1856;
RA   Michaelis M., Rothweiler F., Klassert D., von Deimling A., Weber K.,
RA   Fehse B., Kammerer B., Doerr H.-W., Cinatl J. Jr.;
RT   "Reversal of P-glycoprotein-mediated multidrug resistance by the
RT   murine double minute 2 antagonist nutlin-3.";
RL   Cancer Res. 69:416-421(2009).
//
RX   PubMed=22170099; DOI=10.1038/cddis.2011.129;
RA   Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M.,
RA   Loschmann N., Voges Y., Breitling R., von Deimling A., Rodel F.,
RA   Weber K., Fehse B., Mack E., Stiewe T., Doerr H.-W., Speidel D.,
RA   Cinatl J. Jr.;
RT   "Adaptation of cancer cells from different entities to the MDM2
RT   inhibitor nutlin-3 results in the emergence of p53-mutated
RT   multi-drug-resistant cancer cells.";
RL   Cell Death Dis. 2:e243.1-e243.8(2011).
//
RX   PubMed=22476102; DOI=10.1038/cddis.2012.35;
RA   Michaelis M., Rothweiler F., Agha B., Barth S., Voges Y.,
RA   Loschmann N., von Deimling A., Breitling R., Doerr H.-W., Rodel F.,
RA   Speidel D., Cinatl J. Jr.;
RT   "Human neuroblastoma cells with acquired resistance to the p53
RT   activator RITA retain functional p53 and sensitivity to other p53
RT   activating agents.";
RL   Cell Death Dis. 3:e294.1-e294.8(2012).
//
RX   PubMed=24466371; DOI=10.1593/tlo.13544;
RA   Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J.,
RA   Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A.,
RA   Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.;
RT   "Testing of SNS-032 in a panel of human neuroblastoma cell lines with
RT   acquired resistance to a broad range of drugs.";
RL   Transl. Oncol. 6:685-696(2013).
//
RX   PubMed=25749379; DOI=10.18632/oncotarget.2889;
RA   Michaelis M., Rothweiler F., Loschmann N., Sharifi M., Ghafourian T.,
RA   Cinatl J. Jr.;
RT   "Enzastaurin inhibits ABCB1-mediated drug efflux independently of
RT   effects on protein kinase C signalling and the cellular p53 status.";
RL   Oncotarget 6:17605-17620(2015).
//
RX   PubMed=27517323; DOI=10.18632/oncotarget.11160;
RA   Loschmann N., Michaelis M., Rothweiler F., Voges Y., Balonova B.,
RA   Blight B.A., Cinatl J. Jr.;
RT   "ABCB1 as predominant resistance mechanism in cells with acquired
RT   SNS-032 resistance.";
RL   Oncotarget 7:58051-58064(2016).
//
RX   PubMed=27735941; DOI=10.1038/cddis.2016.257;
RA   Voges Y., Michaelis M., Rothweiler F., Schaller T., Schneider C.,
RA   Politt K., Mernberger M., Nist A., Stiewe T., Wass M.N., Rodel F.,
RA   Cinatl J. Jr.;
RT   "Effects of YM155 on survivin levels and viability in neuroblastoma
RT   cells with acquired drug resistance.";
RL   Cell Death Dis. 7:e2410.1-e2410.11(2016).
//
RX   PubMed=31581737; DOI=10.3390/cells8101194;
RA   Povey J.F., Saintas E., Aderemi A.V., Rothweiler F., Zehner R.,
RA   Dirks W.G., Cinatl J. Jr., Racher A.J., Wass M.N., Smales C.M.,
RA   Michaelis M.;
RT   "Intact-cell MALDI-ToF mass spectrometry for the authentication of
RT   drug-adapted cancer cell lines.";
RL   Cells 8:1194.1-1194.12(2019).
//